Short answer
Humacyte, Inc. (HUMA) filed an 8-K current report with the SEC on June 10, 2026 reporting Item 8.01 (Other Events). Phase 3 V012 results presented for ATEV arteriovenous access in female hemodialysis patients with end-stage renal disease.
Humacyte, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Phase 3 V012 results presented for ATEV arteriovenous access in female hemodialysis patients with end-stage renal disease
- Clinical update targets ATEV’s potential use in vascular access for a defined high-need population
- Investor presentation filed for use during investor calls and conferences, potentially shaping near-term market expectations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Humacyte, Inc. 8-K filings
Get the next HUMA 8-K as it lands
Follow HUMA for push alerts, or ask the research agent what this filing means.